Impact of Matrix Metalloproteinase 9 on COPD Development in Polish Patients: Genetic Polymorphism, Protein Level, and Their Relationship with Lung Function
Table 4
MMP-9 gene polymorphisms impact on MMP-9, MMP-9/TIMP1 and MMP-9/TIMP2 proteins level in serum of COPD patient and healthy control groups.
Proteins levels Genotypes
Groups
p value
COPD patients N=60
CTR N=61
CTR smokers N=23
CTR non-smokers N=38
p1
p2
p3
p4
MMP-9 [ng/ml]
C allele
149.9 ± 72.8
26.5 ± 6.8
27.6 ± 8.3
25.9 ± 5.8
<0.00001
<0.00001
<0.00001
1.0
T allele
130.7 ± 35.9
27.6 ± 8.3
30.4 ± 8.3
22.6 ± 6.3
<0.00001
<0.00001
<0.00001
0.76
CC
152.9 ± 76.9
26.0 ± 5.6
23.9 ± 5.9
26.7 ± 5.4
<0.00001
<0.00001
<0.00001
1.0
CT
130.7 ± 35.9
27.7 ± 9.3
31.0 ± 8.9
20.5 ± 5.9
<0.00001
<0.00001
<0.00001
1.0
TT
-
27.4 ± 2.5
26.9 ± 1.8
27.9 ± 3.9
not tested
not tested
not tested
0.72
2 copies
142.9 ± 64.9
27.1 ± 6.5
27.5 ± 8.3
26.8 ± 5.0
<0.00001
<0.00001
<0.00001
1.0
1 and >2 copies
186.8 ± 101.8
24.2 ± 6.8
27.6 ± 1.7
23.5 ± 7.4
<0.00001
0.006
<0.00001
1.0
MMP-9/TIMP1 [pg/ml]
C allele
3146.8 ± 492.0
2951.4 ± 496.1
3125.0 ± 182.5
2850.1 ± 588.3
0.14
1.0
0.02
0.18
T allele
3232.3 ± 354.0
3072.8 ± 523.1
3181.7 ± 173.3
2870.6 ± 856.2
not tested (ANOVA p>0.05)
CC
3131.7 ± 513.8
2920.0 ± 464.0
3076.2 ± 180.3
2869.7 ± 516.3
not tested (ANOVA p>0.05)
CT
3232.3 ± 354.0
3031.8 ± 578.9
3169.6 ± 181.1
2728.9 ± 1003.9
not tested (ANOVA p>0.05)
TT
-
3236.7 ± 111.6
3248.4 ± 147.3
3229.0 ± 122.9
not tested (ANOVA p>0.05)
2 copies
3132.9 ± 532.7
2968.6 ± 512.7
3129.6 ± 187.2
2852.0 ± 633.6
not tested (ANOVA p>0.05)
1 and >2 copies
3225.9 ± 54.5
2976.9 ± 352.6
3200.6 ± 74.2
2927.3 ± 373.4
not tested (ANOVA p>0.05)
MMP-9/TIMP2 [ng/ml]
C allele
6.2 ± 4.2
6.2 ± 2.0
5.8 ± 1.4
6.5 ± 2.3
not tested (ANOVA p>0.05)
T allele
9.4 ± 8.2
5.7 ± 1.8
5.9 ± 1.3
5.5 ± 2.6
not tested (ANOVA p>0.05)
CC
5.6 ± 2.8
6.3 ± 2.2
5.6 ± 1.6
6.5 ± 2.3
not tested (ANOVA p>0.05)
CT
9.4 ± 8.2
6.0 ± 1.8
6.0 ± 1.3
6.2 ± 2.8
not tested (ANOVA p>0.05)
TT
-
4.5 ± 1.2
5.1 ± 0.2
3.9 ± 1.7
not tested (ANOVA p>0.05)
2 copies
6.3 ± 4.5
6.0 ± 1.6
5.8 ± 1.4
6.0 ± 1.7
not tested (ANOVA p>0.05)
1 and >2 copies
5.5 ± 0.4
6.8 ± 3.5
5.0 ± 0.5
7.1 ± 3.8
not tested (ANOVA p>0.05)
N, number of individuals; COPD, chronic obstructive pulmonary disease groups; CTR, control group; , COPD patients versus CTR; , COPD patients versus CTR smokers; , COPD patients versus CTR nonsmokers; , CTR smokers versus CTR nonsmokers.
